Prostate cancer patients have a limited number of therapeutic options, with very few mechanisms of action (MOAs) targeting their disease. Currently approved agents consist of therapies that target hormones, one class of chemotherapeutic agents (taxanes, such as docetaxel or Jevtana [cabazitaxel]), and a niche cancer vaccine, Provenge, the latter of which is only available in the US (but was withdrawn from the EU market at the request of the manufacturer, Dendreon, for commercial reasons).
Prostate cancer treatment, 2019
Over the next decade, GlobalData expects a large number of new MOAs to enter the market. Most notably, poly ADP ribose polymerase (PARP) inhibitors, including AstraZeneca’s Lynparza (olaparib), Clovis’ Rubraca (rucaparib), Tesaro’s Zejula (niraparib), and Pfizer’s Talzenna (talazoparib) are expected to expand their labels, working their way from ovarian and breast cancer treatments over to prostate cancer.
Other notable label expansions, of immune checkpoint inhibitors, have been dominating the oncology space, and GlobalData expects that Merck’s Keytruda (pembrolizumab) and Roche/Genentech’s Tecentriq (atezolizumab) will enter prostate cancer as well.
The early-stage prostate cancer pipeline has also exploded with agents targeting multiple facets of the disease. GlobalData finds a number of MOAs, novel chemotherapies, agents targeting the immune system, epigenetic therapeutics, and more. In addition, there are new and innovative molecule types in the pipeline, including monoclonal antibodies, antibody-drug conjugates, nanoparticle-drug conjugates, peptides, radiopharmaceuticals, recombinant proteins, and gene therapies, among others. The figure below displays the current clinical development pipeline for prostate cancer.
Clinical development pipeline for prostate cancer, 2019
Source: GlobalData
Forthcoming reports:
GlobalData. Prostate Cancer – Epidemiology Forecast to 2028, to be published
GlobalData. Prostate Cancer – Global Drug Forecast and Market Analysis to 2028, to be published
